NCT05103254Recruiting

Bempedoic Acid Pregnancy Surveillance Program

Esperion Therapeutics, Inc.

Start Date

9/1/2021

Completion Date

5/1/2032

Summary

Bempedoic acid pregnancy surveillance program

Detailed Description

A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome Exclusion Criteria:

Interventions

DRUG

Bempedoic Acid

DRUG

Bempedoic Acid / Ezetimibe

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

PregnancyHyperlipidemias

Locations

Evidera, PPD business unit

Morrisville, North Carolina 27560

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.